

Table 8.3
Denmark

Prices of most common presentation, both locally-sourced and PI, compared with prices of identical presentation in lowest price exporting country and the average of the three lowest exporting countries (in €, all prices are the average price of the four quarters of 2002)

| Product | Prices of PI drug | Prices of locally sourced drugs | Prices in lowest price country | Average of the three lowest price countries |
|---------------------|--------------------------|--|---------------------------------------|--|
| Olanzapine | | | | |
| Risperidone | 78.51 | 80.48 | 55.96 | 68.81 |
| Clozapine | 76.07 | 80.78 | 35.49 | 44.62 |
| Captopril | 44.14 | 46.19 | 24.77 | 26.17 |
| Enalapril | 54.54 | 56.51 | 31.52 | 41.76 |
| Ramipril | 42.72 | 55.19 | 34.39 | 40.99 |
| Quinalapril | 58.68 | 60.68 | 29.42 | 40.57 |
| Losartan | N/a | N/a | N/a | N/a |
| Valsartan | N/a | N/a | N/a | N/a |
| Atorvastatin | 138.75 | 141.30 | 95.42 | 110.46 |
| Pravastatin | N/a | N/a | N/a | N/a |
| Simvastatin | 118.29 | 129.38 | 61.13 | 81.76 |
| Citalopram | 85.12 | 91.17 | 40.17 | 52.11 |
| Fluoxetine | 91.72 | 97.89 | 11.91 | 13.88 |
| Paroxetine | 87.14 | 100.18 | 68.16 | 81.53 |
| Sertraline | 67.80 | 99.50 | 60.97 | 80.35 |
| Lansoprazole | N/a | N/a | N/a | N/a |
| Omeprazole | N/a | N/a | N/a | N/a |
| Pantoprazole | N/a | N/a | N/a | N/a |

Source: Authors' compilations from IMS.

Table 8.4
Germany

Prices of most common presentation, both PI and locally-sourced, compared with prices of identical presentation in lowest price exporting country and the average of the three lowest exporting countries (in €, all prices are the average price of the four quarters of 2002)

| Product | Prices of PI drug | Prices of locally sourced drugs | Prices in lowest price country | Average of the three lowest price countries |
|---------------------|--------------------------|--|---------------------------------------|--|
| Olanzapine | 76.7 | 80.9 | 46.2 | 50.8 |
| Risperidone | 99.5 | 110.8 | 46.7 | 54.8 |
| Clozapine | N/a | N/a | N/a | N/a |
| Captopril | 109.4 | 111.9 | 13.5 | 18.9 |
| Enalapril | 38.4 | 42.5 | 14.4 | 27.4 |
| Ramipril | 46.4 | 47.6 | 31.2 | 33.2 |
| Quinalapril | 54.4 | 59.8 | 35.7 | 42.1 |
| Losartan | N/a | N/a | N/a | N/a |
| Valsartan | 73.8 | 78.3 | 56.4 | 61.8 |
| Atorvastatin | N/a | N/a | N/a | N/a |
| Pravastatin | 74.8 | 81.5 | 59.1 | 62.7 |
| Simvastatin | 135.2 | 141.1 | 49.6 | 73.9 |
| Citalopram | 55.9 | 59.3 | 33.9 | 34.4 |
| Fluoxetine | 104.1 | 115.7 | 64.9 | 57.2 |
| Paroxetine | 99.6 | 115.7 | 63.9 | 72.0 |
| Sertraline | 107.8 | 111.1 | 63.8 | 75.0 |
| Lansoprazole | 31.4 | 38.5 | 14.6 | 16.1 |
| Omeprazole | 18.6 | 27.8 | 12.6 | 15.5 |
| Pantoprazole | 71.9 | 71.9 | 39.0 | 38.4 |

Source: Authors' compilations from IMS.

Table 8.5
The Netherlands

Prices of most common presentation, both PI and locally-sourced, compared with prices of identical presentation in lowest price exporting country and the average of the three lowest exporting countries (in €, all prices are the average price of the four quarters of 2002)

| Product | Prices of PI drug | Prices of locally sourced drugs | Prices in lowest price country | Average of the three Lowest price countries |
|---------------------|--------------------------|--|---------------------------------------|--|
| Olanzapine | 66.3 | 71.7 | 46.1 | 51.0 |
| Risperidone | 95.8 | 108.6 | 46.6 | 56.4 |
| Clozapine | 25.4 | 27.4 | 11.8 | 14.3 |
| Captopril | N/a | N/a | N/a | N/a |
| Enalapril | 16.5 | 19.9 | 9.6 | 11.6 |
| Ramipril | 55.7 | 64.2 | 28.9 | 30.9 |
| Quinalapril | 19.8 | 24.0 | 9.0 | 12.0 |
| Losartan | 22.5 | 25.7 | 16.1 | 17.6 |
| Valsartan | 22.3 | 23.8 | 13.8 | 15.4 |
| Atorvastatin | 49.6 | 63.6 | 37.3 | 37.5 |
| Pravastatin | 54.5 | 57.7 | 41.7 | 42.8 |
| Simvastatin | 38.6 | 44.3 | 18.9 | 22.8 |
| Citalopram | 29.1 | 32.6 | 12.5 | 15.0 |
| Fluoxetine | 20.2 | 24.7 | 12.3 | 14.7 |
| Paroxetine | 32.1 | 35.6 | 20.4 | 24.0 |
| Sertraline | 34.5 | 38.7 | 17.4 | 21.6 |
| Lansoprazole | 28.5 | 30.7 | 10.7 | 14.9 |
| Omeprazole | 23.0 | 29.3 | 9.8 | 13.6 |
| Pantoprazole | 24.4 | 27.9 | 15.3 | 16.7 |

Source: Authors' compilations from IMS.

Table 8.6
Norway

Prices of most common presentation, both PI and locally-sourced, compared with prices of identical presentation in lowest price exporting country and the average of the three lowest exporting countries
(in €, all prices are the average price of the four quarters of 2002)

| Product | Prices of PI drug | Prices of locally sourced drugs | Prices in lowest price country | Average of the three lowest price countries |
|---------------------|--------------------------|--|---------------------------------------|--|
| Olanzapine | 66.88 | 67.37 | 46.10 | 50.19 |
| Risperidone | 36.21 | 47.66 | 30.13 | 32.58 |
| Clozapine | 60.85 | 63.28 | 35.49 | 44.62 |
| Captopril | 43.23 | 44.10 | 35.69 | 33.47 |
| Enalapril | 42.33 | 41.65 | 39.68 | 47.28 |
| Ramipril | 56.49 | 57.03 | 34.39 | 40.99 |
| Quinalapril | N/a | N/a | N/a | N/a |
| Losartan | N/a | N/a | N/a | N/a |
| Valsartan | N/a | N/a | N/a | N/a |
| Atorvastatin | 232.35 | 246.68 | 145.44 | 170.28 |
| Pravastatin | 109.12 | 111.88 | 69.13 | 77.90 |
| Simvastatin | 126.98 | 128.48 | 61.13 | 81.76 |
| Citalopram | 91.03 | 91.90 | 39.37 | 51.07 |
| Fluoxetine | 54.04 | 88.22 | 11.91 | 13.88 |
| Paroxetine | 99.13 | 100.20 | 63.90 | 69.54 |
| Sertraline | N/a | N/a | N/a | N/a |
| Lansoprazole | N/a | N/a | N/a | N/a |
| Omeprazole | 165.71 | 167.49 | 65.50 | 85.28 |
| Pantoprazole | N/a | N/a | N/a | N/a |

Source: Authors' compilations from IMS.

Table 8.7

Sweden

Prices of most common presentation, both PI and locally-sourced, compared with prices of identical presentation in lowest price exporting country and the average of the three lowest exporting countries (in €, all prices are the average price of the four quarters of 2002)

| Product | Prices of PI drug | Prices of locally sourced drugs | Prices in lowest price country | Average of the three lowest price countries |
|---------------------|--------------------------|--|---------------------------------------|--|
| Olanzapine | 272.4 | 311.8 | 176.0 | 193.1 |
| Risperidone | 272.4 | 311.8 | 176.0 | 193.1 |
| Clozapine | 44.9 | 52.4 | 30.1 | 32.7 |
| Captopril | N/a | N/a | N/a | N/a |
| Enalapril | 70.3 | 83.3 | 30.0 | 41.7 |
| Ramipril | 51.7 | 60.2 | 34.4 | 41.0 |
| Quinalapril | N/a | N/a | N/a | N/a |
| Losartan | N/a | N/a | N/a | N/a |
| Valsartan | N/a | N/a | N/a | N/a |
| Atorvastatin | 91.0 | 103.2 | 54.8 | 69.1 |
| Pravastatin | 91.1 | 96.9 | 69.1 | 77.9 |
| Simvastatin | N/a | N/a | N/a | N/a |
| Citalopram | 68.6 | 70.5 | 43.2 | 46.5 |
| Fluoxetine | 112.5 | 104.4 | 11.8 | 14.5 |
| Paroxetine | 354.7 | 181.3 | 24.7 | 29.0 |
| Sertraline | 150.2 | 185.1 | 66.3 | 86.6 |
| Lansoprazole | N/a | N/a | N/a | N/a |
| Omeprazole | N/a | N/a | N/a | N/a |
| Pantoprazole | N/a | N/a | N/a | N/a |

Source: Authors' compilations from IMS.

Table 8.8
United Kingdom


Prices of most common presentation, both PI and locally-sourced, compared with prices of identical presentation in lowest price exporting country and the average of the three lowest exporting countries (in €, all prices are the average price of the four quarters of 2002)

| Product | Prices of PI drug | Prices of locally sourced drugs | Prices in lowest price country | Average of the three lowest price countries |
|---------------------|--------------------------|--|---------------------------------------|--|
| Olanzapine | 153.6 | 153.6 | 88.0 | 96.9 |
| Risperidone | 125.2 | 125.2 | 56.0 | 67.6 |
| Clozapine | N/a | N/a | N/a | N/a |
| Captopril | 18.9 | 18.9 | 6.9 | 10.1 |
| Enalapril | 19.7 | 19.7 | 9.0 | 12.1 |
| Ramipril | N/a | N/a | N/a | N/a |
| Quinalapril | 11.3 | 11.3 | 2.7 | 3.8 |
| Losartan | 27.1 | 27.1 | 16.1 | 17.7 |
| Valsartan | 24.8 | 24.8 | 13.8 | 16.9 |
| Atorvastatin | 28.4 | 28.4 | 15.3 | 19.4 |
| Pravastatin | 46.7 | 46.7 | 19.7 | 22.4 |
| Simvastatin | 46.7 | 46.7 | 17.7 | 23.2 |
| Citalopram | 25.2 | 25.2 | 12.5 | 15.0 |
| Fluoxetine | 22.4 | 24.4 | 11.4 | 13.8 |
| Paroxetine | 49.0 | 70.3 | 20.4 | 25.0 |
| Sertraline | 41.7 | 41.7 | 24.4 | 28.7 |
| Lansoprazole | 37.4 | 37.4 | 25.0 | 29.0 |
| Omeprazole | 45.0 | 45.0 | 9.4 | 12.9 |
| Pantoprazole | 37.2 | 37.2 | 18.1 | 18.1 |


Source: Authors' compilations from IMS.

Figure 8.1: Relative price graphs $(\frac{P_{import}}{P_{export}})^{1,2}$


Relative prices with lowest country
Atorvastatin




Relative prices with lowest country
Pravastatin




Relative prices with lowest country
Simvastatin




Relative prices with lowest country
Captopil




Relative prices with lowest country
Enalapril




Relative prices with lowest country
Quinalapril




**Relative prices with lowest country
Ramipril**




**Relative prices with lowest country
Losartan**




Relative prices with lowest country Clozapine




**Relative prices with lowest country
Omeoprazole**




**Relative prices with lowest country
Pantoprazole**




**Relative prices with lowest country
Olanzapine**



**Relative prices with lowest country
Risperidone**



**Relative prices with lowest country
Lanzoprazole**



Note: ¹ If relative prices ($\frac{P^{orig}}{P^{orig*}}$) > 1, this means that destination country prices (P^{orig}) are above the prices of the lowest country (P^{orig*}). Prices are DDD and pill-adjusted

² In this graph we included 14 of the 19 products. We did not include the remaining products because there were either too many missing observations (therefore a sufficient time-series would not have been able to be constructed) for a given period for the most common presentation in the set of countries chosen (Losartan plus the SSRI drugs).

Source: Authors' calculations from IMS.

References

- ⁱ Philipson A. *guide to the concept and practical application of articles 28-30 EC*, Commission of the European Communities, DG Enterprise, Brussels, January 2001.
- ⁱⁱ Joint Cases C-427/93, C-429/93, C-436/93 Bristol-Myers Squibb v. Paranova [1997] ESR 102.
- ⁱⁱⁱ European Court of Justice, ECJ Case C-443/99 Merck, Sharp & Dohme GmbH v. Paranova Pharmazeutika Handels GmbH, 1999.
- ^{iv} European Court of Justice, ECJ Case C-143/00 Boehringer Ingelheim GmbH, Glaxo Group Ltd and others v. Dowelhurst Ltd and Swingward Ltd, 2000.
- ^v European Court of Justice, ECJ Cases C-267/95 and C-268/95 Merck and Others v. Primecrown and Others and Beecham Group v Europharm of Worthing, Judgment of 5th December 1996.
- ^{vi} European Court of Justice, ECJ Case T-41/96 Bayer AG v. Commission of the European Communities, Judgement of 26 October 2000.
- ^{vii} European Court of Justice, ECJ Case C-433/00 Aventis Pharma Deutschland GmbH v. Kohlfarma GmbH and MTK Pharma Vertrieb-GmbH, Comment of 19 September 2002.
- ^{viii} European Court of Justice, Judgment of the Court of Justice in Joined Cases C-2/01 P and C-3/01 P: *Bundesverband der Arzneimittel-Importeure and Commission of the European Communities v Bayer AG*; Press Release No. 01/04, <http://curia.eu.int/jurisp/cgi-bin/form.pl?lang=en&Submit=Submit&docrequire=alldocs&numaff=C-2%2F01+P&datefs=&datefe=&nomusuel=&domaine=&mots=&resmax=100>; 6 January 2004, accessed 9 January 2004.
- ^{ix} European Court of Justice, *Common Origin not prerequisite for parallel trade*, Opinion, ECJ case C-112/02, Kohlfarma GmbH vs. Federal Republic of Germany, 12 September 2003.
- ^x Maskus KE. Parallel imports in a model of vertical distribution: theory, evidence and policy. *Pacific Economic Review*, 2002;7:319-334.
- ^{xi} Knox D, Richardson M. Trade policy and parallel imports. *European Journal of Political Economy*, 2002;19:133-151.
- ^{xii} Richardson M. An elementary proposition concerning parallel imports. *Journal of International Economics*, 2002;56:233-245.
- ^{xiii} Maskus KE, Chen Y. Vertical Price Control and Parallel imports: Theory and Evidence. *Review of International Economics* 2003 (forthcoming).
- ^{xiv} Ahmadi R, Yang BR. Parallel imports: challenges from unauthorized distribution channels. *Marketing Science*, 2000;19(3):279-294.
- ^{xv} Malueg DA, Schwarz M. Parallel Imports, demand dispersion and International Price Discrimination. *Journal of International Economics*, 1994;37:187-196.
- ^{xvi} Danzon P. The Economics of parallel trade, *Pharmacoeconomics*. 1998;13:293-304.
- ^{xvii} Linnosmaa I, Karhunen T, Vohlonen I. Parallel importation of pharmaceuticals in Finland: Effects on markets and expenditures. *Pharmaceutical Development and Regulation*. 2003;1:67-74.
- ^{xviii} West P, Mahon J. *Benefits to payers and patients from parallel trade*. York Health Economics Consortium, York, May 2003, <http://www.yhec.co.uk>.
- ^{xix} Arfwedson J. *Parallel trade in pharmaceuticals*, 2003.

- ^{xx} NERA, SJ Berwin & Co. *The Economic consequences of the choice of regime of exhaustion in the area of trademarks*, London, 8th February 1999.
- ^{xxi} Urch Publishing. *Pharmaceutical Parallel Trade*, Urch Publishing, London, June 1st, 1999.
- ^{xxii} Reuters Business Insight. *The global parallel trade outlook 2001-2006: A country-by-country analysis*, Reuters Business Insight, 2001.
- ^{xxiii} Macarthur D. *Parallel trade with medicines in Europe: the facts*, <http://www.eaepc.org>, accessed and downloaded 12 September 2003.
- ^{xxiv} West P, Mahon J. *Benefits to payers and patients from parallel trade*. York Health Economics Consortium, York, May 2003, <http://www.yhec.co.uk>.
- ^{xxv} European Association of Euro-Pharmaceutical Companies. *Parallel trade of pharmaceuticals: why does parallel trade exist? How does parallel trade work? The effects of parallel trade*. <http://www.eaepc.org>.
- ^{xxvi} Linnosmaa I, et al. 2003, op. cit.
- ^{xxvii} Ganslandt M, Maskus KE. Parallel imports of pharmaceutical products in the European Union. *The Research Institute of Industrial Economics*, Working Paper No 546, 2001.
- ^{xxviii} Ganslandt M, Maskus KE. 2001, op. cit.
- ^{xxix} Ahmadi R, Yang BR. Parallel imports: challenges from unauthorised distribution channels. *Marketing Science*, 2000;19(3):279-294.
- ^{xxx} Danzon P. The Economics of parallel trade, *Pharmacoeconomics*. 1998;13:293-304.
- ^{xxxi} Kanavos P. Single currency and monetary union: macroeconomic implications for pharmaceutical spending. *Pharmacoeconomics*, 1998; 13(1 Pt 1):9-20.
- ^{xxxii} Kanavos P. The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings. *Pharmacoeconomics*; 2000; 18(6):523-532.
- ^{xxxiii} West P, Mahon J. 2003, op. cit
- ^{xxxiv} Ganslandt M, Maskus KE. *Parallel imports of pharmaceutical products in the European Union*. The Research Institute of Industrial Economics, Working Paper No 546; 2001.
- ^{xxxv} Abbott FM. First Report (Final) to the Committee on International Trade Law of the International Law Association on the Subject of Parallel Importation, *Journal of International Economic Law* 1998;1:607-636.
- ^{xxxvi} Abbott, F. M. (1998), op.cit.
- ^{xxxvii} Knox D, Richardson M. Trade policy and parallel imports. *European Journal of Political Economy* March 2003;19(1):133-151.
- ^{xxxviii} Mauleg D, Schwartz M. Parallel Imports, Demand Dispersion and International Price Discrimination. *Journal of International Economics*. 1994;(37).
- ^{xxxix} Maskus K. Parallel Imports. *World Economy*, 2000.
- ^{xl} Barfield CE, Groombdirge MA, 1998, Op. cit.
- ^{xli} Mauleg D, Schwartz M. 1994, op.cit.
- ^{xlii} Gallini N, Hollis A. A contractual approach to the gray market. *International Review of Law and Economics* 1999; 19, pp. 1–21.
- ^{xliii} Mauleg D. Schwartz M, 1994, op. cit.
- ^{xliv} Richardson M. An elementary proposition concerning parallel imports. *Journal of International Economics* , January 2002; 56(1): 233-245.
- ^{xlv} Mauleg D. and Schwartz M. 1994, op. cit.
- ^{xlvi} Mauleg D. and Schwartz M, 1994, op. cit.
- ^{xlvii} Chard JS, Mellor CJ. Intellectual Property Rights and Parallel Imports, *The World Economy*. 1989;12, 69-83.

- ^{xlvi} Barfield CE, Groombridge MA. 1998, op. cit.
- ^{xlvi} Richardson M. 2002, op. cit.
- ¹ Knox D, Richardson M. Trade policy and parallel imports. *European Journal of Political Economy* Volume 19, Issue 1, March 2003, Pages 133-151.
- ⁱⁱ Kenny P, McNutt P. *Competition, Parallel Imports & Trademark Exhaustion: two Wrongs from a Trademark Right*. Competition Authority, United Kingdom. Discussion Paper, 1999.
- ⁱⁱⁱ Maskus KE. Parallel imports in pharmaceuticals: implications for competition and prices in developing countries. *Final Report to the World Intellectual Property Organisation*, April 2001.
- ⁱⁱⁱⁱ Mauleg D, Schwartz M. 1994, op. cit.
- ^{lv} Valletti TM, Szymanski S. *Parallel Trade, International Exhaustion and Intellectual Property Rights: A Welfare Analysis*, CEPR Discussion Paper, 2003.
- ^{lv} Mauleg D, Schwartz M. 1998, op. cit.
- ^{lvi} Borodoy C, Jelovac I. *Pricing and welfare implications of parallel imports in the pharmaceutical industry*. MERIT, Maastricht Economic Research, Institute on Innovation and Technology Working Paper 4, the Netherlands, 2003.
- ^{lvii} Mauleg D, Schwartz M. 1998, op. cit.
- ^{lviii} Hausman JA, MacKie-Mason JK. Price discrimination and patent policy, *RAND Journal of Economics*, 1988;19: 253-265.
- ^{lix} Valletti TM, Szymanski, S. 2003. *Parallel Trade, International Exhaustion and Property Rights: a welfare analysis*. Imperial College of Science and Technology, Mimeo.
- ^{lx} West P, Mahon J. 2003, op. cit.
- ^{lxi} Mauleg D, Schwartz M. 1998, op. cit.
- ^{lxii} Kanavos P. 1998, op.cit.
- ^{lxiii} Hilke JC. Free-trading or free-riding: An Examination of the Theories and available Empirical Evidence on Grey Market Imports. *World Competition* 1988;32.
- ^{lxiv} Maskus & Chen, 1999. 1999. Vertical price control and parallel imports. Mimeo, University of Colorado at Boulder, USA.
- ^{lxv} Gallini N, Hollis A. A contractual approach to the gray market. *International Review of Law and Economics* 1999;19:1-21.
- ^{lxvi} Abbott, 1998, op. cit.
- ^{lxvii} Tarr D. *An Economic Analysis of Grey Market Imports*, US Federal Trade Commission, Washington, DC., 1985.
- ^{lxviii} Hilke JC. Free Trading and Free Riding: an examination of the theories and available evidence on Grey Market Imports. *World Competition* 32: 75-92, 1988.
- ^{lxix} Varian HR. Price Discrimination and social welfare. *American Economic Review*, 1985; 75: 870-5.
- ^{lxx} Malueg and Schwartz, 1994, op. cit.
- ^{lxxi} Malueg and Schwartz, 1994, op. cit.
- ^{lxxii} Abbott, 1998, op.cit.
- ^{lxxiii} Kanavos P. 1998, op. cit.
- ^{lxxiv} Kanavos P. 2000, op. cit.
- ^{lxxv} Kanavos P, Mossialos E. Outstanding regulatory issues in the European pharmaceutical market. *Pharmacoeconomics*. 2000.
- ^{lxxvi} Palia AP, Keown CF. Combating parallel importing: Views of U.S. exporters to the Asia-Pacific region. *International Marketing Review*. 1991; 8 (1): 47-56.

- ^{lxxvii} Abbott, 1998, op.cit.
- ^{lxxviii} Ganslandt M, Maskus KE. 2001. op. cit.
- ^{lxxix} Linnosmaa I, Karhunen T, Vohlonen I. Parallel importation of pharmaceuticals in Finland: Effects on markets and expenditures. *Pharmaceutical Development and Regulation*, 2003; 1:67-74.
- ^{lxxx} West P, Mahon J. 2003, op.cit.
- ^{lxxxi} Maskus KE. *World Economy*, 2000.
- ^{lxxxii} Krugman PR, And Obstfeld M. *International Economics: Theory and Policy*, Harper Collins, second edition, 1991.
- ^{lxxxiii} Ganslandt M, Maskus KE. 2001, op. cit.
- ^{lxxxiv} Linnosmaa I, et al 2003, op.cit.
- ^{lxxxv} Persson U, Anell A, Persson M. *Swedish Institute of Health Economics*, Abstract No. 763, 2003.
- ^{lxxxvi} West P, Mahon J. 2003, op. cit.
- ^{lxxxvii} Varian HR. *Intermediate Microeconomics*, Norton, second edition, 1989.
- ^{lxxxviii} Danzon P. 1998, op.cit.
- ^{lxxxix} Varian HR. 1989, op.cit.
- ^{xc} Intercontinental Medical Statistics (IMS), *Acts 2002*, IMS Health Quality Assurance, 2002.
- ^{xci} Danzon P, Chao LW. Cross-national price differences for pharmaceuticals: How large and why? *Journal of Health Economics*, 2000;19:159-195.
- ^{xcii} Hitiris T. Prescription Charges in the United Kingdom: a critical review. Discussion Papers in Economics 4/2000, Department of Economic and Related Studies; University of York, 2000..
- ^{xciii} Kanavos P. The single market for pharmaceuticals in the European Union in light of European Court of Justice Rulings. *Pharmacoeconomics*, 2000 (December);18(6):523-32.
- ^{xciv} Kanavos P. Single European market and Monetary Union: Macroeconomic implications for pharmaceutical spending. *Pharmacoeconomics*, 1998 (January); 13(1 Pt 1):9-20.
- ^{xcv} Kontozamanis V, Mantzouneas E, Stoforos C. An overview of the Greek pharmaceutical market. *European Journal of Health Economics*, 2003; 4:327-333.
- ^{xcvi} Estimates by the main health insurance fund (IKA) for 2002.
- ^{xcvii} Danzon P. The Economics of parallel trade, *Pharmacoeconomics*, 1998.
- ^{xcviii} Kanavos P. Encouraging parallel trade of medicines in Europe: towards improved economic efficiency and improved resource allocation? Mimeo, 2003.
- ^{xcix} West P, Mahon J. 2003, op. cit.
- ^c Macarthur D. Submission to G-10 Medicines, 2002.
- ^{ci} West P, Mahon J. 2003, op. cit.
- ^{cii} Hellenic Republic, Hellenic National Drug Organisation, *Establishment of a database for parallel exports by wholesalers*, (Circular). Athens, 3 October 2001.
- ^{ciii} Hellenic Republic, Hellenic National Drug Organisation, *Ensuring adequate supply of pharmaceutical products in the Greek market*, (Circular). Athens, 27 November 2001.
- ^{civ} Kingdom of Spain, Ministerio de Sanidad y Consumo, Decreto ley 725-2003, modifying article 10 of the medicines law, Madrid, May 2003.
- ^{cv} Dutch Foundation on Pharmaceutical data (SFK). (2003a), Markt in beroering, *Pharmaceutisch Weekblad*, 138(21).

-
- ^{cvi} Dutch Foundation on Pharmaceutical data (SFK). (2003b), *Data en Feiten 2003*, Den Haag: Stichting Farmaceutische Kengetallen.
- ^{cvii} Kanavos P. *Pharmaceutical Pricing and Reimbursement in Europe – 1999 Edition*, PJB Publications, Surrey, UK, 1999.
- ^{cviii} Kanavos P. *Pharmaceutical Pricing and Reimbursement in Europe – 2002*, PJB Publications, Surrey, UK, May 2002.
- ^{cix} West P, Majon J. 2003, op.cit.
- ^{cx} Ganslandt M, and Maskus KE. 2001, op.cit.
- ^{cxii} Linnosmaa I, et al 2003, op.cit.
- ^{cxiii} Tirole J. *The theory of Industrial Organisation*, Cambridge Massachusetts: MIT Press, 1989.
- ^{cxiii} Von Stackelberg H. *Marktform und Gleichgewicht*, Vienna: Julius Springer, 1934.